Ozempic Maker Novo Nordisk has a weight problem

Ozempic Maker Novo Nordisk has a weight problem

October 23, 2023, 11:39 a.m. ET

The company behind the diabetes and obesity phenomena, Ozempic and Wegovy, is overweight.

Novo Nordisk became Europe’s most valuable company last month, overtaking luxury goods maker LVMH, which itself took the title from food company Nestlé in 2021. All three companies are global stars that dominate the small European stages where they play, but the Danish pharmaceutical company is now an extreme case. This could be one reason why the shares are trading at a lower price than their closest U.S.-listed counterparts. Elie Lilly.

Copyright ©2023 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8



With a penchant for words, Eleon Smith began writing at an early age. As editor-in-chief of his high school newspaper, he honed his skills telling impactful stories. Smith went on to study journalism at Columbia University, where he graduated top of his class. After interning at the New York Times, Smith landed a role as a news writer. Over the past decade, he has covered major events like presidential elections and natural disasters. His ability to craft compelling narratives that capture the human experience has earned him acclaim. Though writing is his passion, Eleon also enjoys hiking, cooking and reading historical fiction in his free time. With an eye for detail and knack for storytelling, he continues making his mark at the forefront of journalism.
Back to top button